9. All patients must have an improvement in FEV1 not less than 12 % above baseline and an absolute change of at least 200 mL within 15-30 min after administration of 400 mcg salbutamol/albuterol hydroflouroalkane (HFA) MDI., as demonstrated at Visit 1 or during one of the visits during the run-in period.